Telomir Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Telomir Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2023 to Q3 2024.
  • Telomir Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$5.99M, a 250% decline year-over-year.
  • Telomir Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$23M.
  • Telomir Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$13.1M, a 1430% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$23M -$5.99M -$4.28M -250% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$18.7M -$1.45M +$101K +6.54% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$18.8M -$6.25M -$5.77M -1195% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$13.1M -$9.33M Oct 1, 2023 Dec 31, 2023 10-Q 2024-05-13
Q3 2023 -$1.71M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$1.55M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$483K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.